Feasibility Trial on Combination of Platinum Doublets and Hypofractionated Radiotherapy for Locally-advanced Stage and / or Inoperable Non-small Cell Lung Carcinoma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Cisplatin (Primary) ; Etoposide (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms HYPOLAN
- 26 Sep 2017 Planned End Date changed from 1 Dec 2019 to 1 Oct 2021.
- 26 Sep 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Oct 2019.
- 26 Sep 2017 Planned initiation date changed from 1 Dec 2016 to 1 Oct 2017.